KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Total Current Liabilities (2016 - 2025)

Acadia Pharmaceuticals has reported Total Current Liabilities over the past 16 years, most recently at $277.1 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $277.1 million for Q4 2025, down 29.82% from a year ago — trailing twelve months through Dec 2025 was $277.1 million (down 29.82% YoY), and the annual figure for FY2025 was $277.1 million, down 29.82%.
  • Total Current Liabilities for Q4 2025 was $277.1 million at Acadia Pharmaceuticals, down from $356.6 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for ACAD hit a ceiling of $394.9 million in Q4 2024 and a floor of $88.2 million in Q3 2021.
  • Median Total Current Liabilities over the past 5 years was $217.0 million (2023), compared with a mean of $220.9 million.
  • Biggest five-year swings in Total Current Liabilities: skyrocketed 102.38% in 2023 and later dropped 29.82% in 2025.
  • Acadia Pharmaceuticals' Total Current Liabilities stood at $96.1 million in 2021, then soared by 30.77% to $125.6 million in 2022, then skyrocketed by 102.38% to $254.3 million in 2023, then soared by 55.31% to $394.9 million in 2024, then dropped by 29.82% to $277.1 million in 2025.
  • The last three reported values for Total Current Liabilities were $277.1 million (Q4 2025), $356.6 million (Q3 2025), and $330.0 million (Q2 2025) per Business Quant data.